Sciwind Biosciences' Ecnoglutide Accepted for Review by China's NMPA for Type 2 Diabetes
CompanyDrug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes

China General Technology's Henan Topfond Pharmaceutical Faces Executive Investigations
Company

Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation

Leman Biotech Advances Automated CAR-T Production with Zhongshan Life Science Park Move
Company

Leman Biotech Enters Zhongshan Life Science Park to Accelerate CAR-T Innovation

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline
Company

BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
Company

Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
CompanyDrug

HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC

First Patient Dosed in Abbisko's Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors
CompanyDrug

First Patient Dosed in Abbisko’s Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors

Bayer's Nubeqa Files for FDA Approval in mHSPC
CompanyDrug

Bayer’s Nubeqa Files for FDA Approval in mHSPC

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion
Company

MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China
CompanyDeals

Zai Lab Ltd Partners with Pfizer for Commercialization of Xacduro in China

China Grants Marketing Approval for MSD's Welireg for von Hippel-Lindau Disease Tumors
CompanyDrug

China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors

Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance
Company

Medtronic Reports 5% Organic Revenue Growth in Q2 FY25 with Strong Portfolio Performance